GAMMA Investing LLC Has $313,000 Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

GAMMA Investing LLC boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 32.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,295 shares of the company’s stock after buying an additional 557 shares during the quarter. GAMMA Investing LLC’s holdings in Neurocrine Biosciences were worth $313,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NBIX. Ashton Thomas Private Wealth LLC bought a new position in shares of Neurocrine Biosciences during the second quarter worth about $28,000. Blue Trust Inc. increased its position in Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after purchasing an additional 220 shares during the period. Plato Investment Management Ltd raised its holdings in Neurocrine Biosciences by 44.1% during the 2nd quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock worth $59,000 after purchasing an additional 130 shares during the last quarter. Truvestments Capital LLC acquired a new position in shares of Neurocrine Biosciences in the 3rd quarter worth approximately $63,000. Finally, True Wealth Design LLC boosted its stake in shares of Neurocrine Biosciences by 11,740.0% in the 3rd quarter. True Wealth Design LLC now owns 592 shares of the company’s stock valued at $68,000 after purchasing an additional 587 shares during the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $136.85 on Tuesday. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.95 and a fifty-two week high of $157.98. The firm’s 50-day simple moving average is $128.52 and its 200 day simple moving average is $130.83. The stock has a market cap of $13.86 billion, a PE ratio of 36.69 and a beta of 0.33.

Analyst Ratings Changes

A number of equities analysts recently weighed in on NBIX shares. Barclays lifted their target price on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a research note on Monday, December 23rd. StockNews.com downgraded Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Piper Sandler restated an “overweight” rating and set a $160.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. Raymond James reiterated an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, December 20th. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $166.29.

Insider Transactions at Neurocrine Biosciences

In related news, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the sale, the insider now directly owns 15,449 shares in the company, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Ingrid Delaet sold 1,091 shares of the company’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total value of $147,285.00. Following the completion of the transaction, the insider now owns 2,507 shares of the company’s stock, valued at $338,445. This trade represents a 30.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,694 shares of company stock worth $479,230 in the last 90 days. Insiders own 4.30% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.